Quantcast

FDA OKs Neuralstem’s ALS clinical trial

Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, said it received approval from the Food and Drug Administration to begin a Phase II trial using spinal cord-derived human neural stem cells to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

[index]
[index]
[i]
[i]
[id, count]
[id, count]
[f.tagName.toLowerCase()]
[f.tagName.toLowerCase()]
[id, validationType, arg1, arg2]
[id, validationType, arg1, arg2]
[field.tagName.toLowerCase()]
[field.tagName.toLowerCase()]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]